Inflammatory biomarkers in the evaluation of two-year outcomes of omalizumab treatment in severe allergic asthma.
J. Hermanowicz-Salamon (Warsaw, Poland), P. Nejman-Gryz (Warsaw, Poland), R. Rubinsztajn (Warsaw, Poland)
Source: International Congress 2018 – Biomarkers for evaluating asthma
Session: Biomarkers for evaluating asthma
Session type: Thematic Poster
Disease area: Airway diseases
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Related content which might interest you: